Drug Pricing Investigation: Industry Spending on Buybacks, Dividends, and Executive Compensation

Thumbnail Image
Serial Number
Levin Center Identifier
Document Date
Report Length
13 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Found Using Methodology
Idependent Author(s)
Brief Executive Summary
The House Committee on Oversight and Reform investigated pharmaceutical pricing, revealing the industry's targeted price increases in the U.S. The report analyzes financial data from the world's 14 largest drug companies, exposing higher spending on buybacks and dividends than on research and development (R&D). The report challenges industry claims that reduced drug prices would stifle innovation, showing that these companies spent $56 billion more on buybacks and dividends than on R&D from 2016 to 2020. The report also states that spending labeled as R&D often aims to suppress generic competition and maintain monopoly prices.
Press Releases and Contextual Information
Related Hearings
Authors–Congress Members
Authors–Staff Members
Authors–Ex Officio Members
Authors–Additional, Minority, Dissenting Views